Browsing: Lexicon’s chief executive officer. “We expect this important innovation to be commercially available in the U.S. market by the end of June 2023.” The approval is based on two randomized

The US Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals’ drug Sotagliflozin for a broad treatment of heart failure,…